Phase 2 Clinical Trial of GH001 in Postpartum Depression

Summary

This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 female participants with clinically diagnosed postpartum depression (PPD) will be included in this study. The participants will receive an individualized dosing regimen (IDR) with at least one and up to three doses of GH001 administered within a single day.

Timeline

Start

2023-03-02

Primary completion

2024-08-02

Completion

2024-11-15

Publications

• Johnson M, Aceves Baldo P, Arbe E, Brennan B, Cohen SE, Doolin K, Gann W, Gregory D, Keady S, Kriger K, MacIsaac R, Ratcliffe S, Rubinow DR, Svendsen CB, Terwey TH, Tully D, Valcheva V, Zantvoord JB, Deligiannidis KM. Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial. J Clin Psychiatry. 2026 Jun 3;87(3):25m16284. doi: 10.4088/JCP.25m16284.

Drugs

Indications